Astrazeneca (AZN) Other Non-Current Liabilities (2009 - 2020)

Astrazeneca has reported Other Non-Current Liabilities for 11 years, with the latest figure at $298.8 million in Q4 2020.

• On a quarterly basis, Other Non-Current Liabilities rose 12.5% year-over-year to $298.8 million in Q4 2020; TTM through Dec 2020 was $298.8 million, a 12.5% increase from a year earlier, with the FY2020 full-year figure at $298.8 million, up 12.5% from the prior year.
• Other Non-Current Liabilities was $298.8 million for Q4 2020 at Astrazeneca, up from $265.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $298.8 million in Q4 2020, with the low at -$13.0 million in Q4 2017.
• Average Other Non-Current Liabilities over 4 years is $176.8 million, with a median of $210.6 million recorded in 2018.
• The sharpest annual moves came in 2018 and 2020: Other Non-Current Liabilities surged 1296.92% in 2018, then rose 12.5% in 2020.
• Over 4 years, Other Non-Current Liabilities stood at -$13.0 million in 2017, then soared by 1296.92% to $155.6 million in 2018, then surged by 70.69% to $265.6 million in 2019, then increased by 12.5% to $298.8 million in 2020.
• The last three Other Non-Current Liabilities figures came in at $298.8 million (Q4 2020), $265.6 million (Q4 2019), and $155.6 million (Q4 2018), per Business Quant data.